Endometritis

disease
On this page

Also known as endometrium inflammationinflammation of endometriumuterine infection

Summary

Endometritis (MONDO:0000918) is a disease and 25 clinical trials. Top therapeutic interventions include doxycycline anhydrous, cefazolin, and ampicillin. A subtype of endometrial disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 25

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameendometritis
Mondo IDMONDO:0000918
EFOEFO:1001312
MeSHD004716
DOIDDOID:1002
NCITC26764
SNOMED CT78623009
UMLSC0014179
MedGen41789
Is cancer (heuristic)no

Also known as: endometrium inflammation · inflammation of endometrium · uterine infection

Disease family

This is a subtype of endometrial disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorderfemale reproductive system disorderuterine disorderendometrial disorderendometritis

Related subtypes (6): tamoxifen-related endometrial lesion, endometriosis, atypical endometrial hyperplasia, endometrial polyp, adenomyosis, endometrium neoplasm

Subtypes (3): acute endometritis, chronic endometritis, endomyometritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
ClindamycinApproved (phase 4)
Clindamycin PhosphateApproved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ceftriaxone.

Clinical trials & evidence

Clinical trials

Clinical trials: 25.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified20
PHASE42
PHASE22
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00547170PHASE4COMPLETEDDoxycycline Prophylaxis at Vacuum Aspiration Trial
NCT01721616PHASE4WITHDRAWNComparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis
NCT02742948PHASE2UNKNOWNThe Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section
NCT03960970PHASE2UNKNOWNTwo-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries
NCT01587495PHASE1TERMINATEDPharmacokinetics and Safety of Ertapenem in the Postpartum Period
NCT07265505Not specifiedNOT_YET_RECRUITINGStudy of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and/or Recurrent Pregnancy Loss
NCT07603492Not specifiedRECRUITINGFertility Outcomes After Antibiotic Treatment In Women With Chronic Endometritis
NCT00330278Not specifiedCOMPLETEDTiming of Prophylactic Antibiotics for Cesarean Sections
NCT00386477Not specifiedTERMINATEDVaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial
NCT00500019Not specifiedCOMPLETEDUterine Flora During Elective and Urgent Cesarean Sections
NCT00501033Not specifiedCOMPLETEDA Prospective Comparative Study of Induction of Labor With a Cervical Ripening Double Balloon vs Foley Catheter
NCT00603603Not specifiedCOMPLETEDControlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity
NCT00858832Not specifiedCOMPLETEDReduction of Endometritis After Cesarean Section With the Routine Use of Methergine
NCT01235546Not specifiedCOMPLETEDStudy of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection
NCT01464840Not specifiedCOMPLETEDThe Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery
NCT01762098Not specifiedCOMPLETEDChronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization
NCT01945450Not specifiedUNKNOWNProphylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial
NCT02402907Not specifiedCOMPLETEDSTRIPES Study: Study To Reduce Infection Post cEsarean Section
NCT03442218Not specifiedCOMPLETEDUse of Antiseptic Solution for Vaginal Wash Before Cesarean Section
NCT03459599Not specifiedCOMPLETEDAntibiotic Prophylaxis in Ragged Placental Membranes
NCT04163679Not specifiedTERMINATEDVaginal Preparation and Azithromycin to Reduce Post Cesarean Infections
NCT04197167Not specifiedUNKNOWNMid-Infrared Spectroscopy as a Real Time Diagnostic Tool for Chronic Endometritis
NCT04307069Not specifiedUNKNOWNManagement of Prelabor Rupture of the Membranes at Term
NCT05049395Not specifiedUNKNOWNHFNO Reducing the Incidence of Hypoxia for Hysteroscopy Sedated With Propofol
NCT06936475Not specifiedCOMPLETEDVaginal Cleansing With Chlorhexidine Versus Iodine for Prevention of Endometritis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
DOXYCYCLINE ANHYDROUS43
CEFAZOLIN42
AMPICILLIN41
AZITHROMYCIN41
CEFOXITIN SODIUM41
CEFTRIAXONE41
ERTAPENEM41
GENTAMICIN41
METHYLERGONOVINE MALEATE41
CHEMBL429938101
CHEMBL542167801
CHEMBL162801
1701
GENTAMICIN C101